Associations of Ki-ras proto-oncogene mutation and p53 gene overexpression in sporadic colorectal adenomas with demographic and clinicopathologic characteristics

被引:33
作者
Einspahr, Janine G.
Martinez, Maria Elena
Jiang, Ruiyun
Hsu, Chiu-Hsieh
Bhattacharrya, Achyut K.
Ahnen, Dennis J.
Jacobs, Elizabeth T.
Houlihan, P. Scott
Webb, C. Renee
Alberts, David S.
Hamilton, Stanley R.
机构
[1] Univ Arizona, Arizona Canc Ctr, Dept Med, Tucson, AZ 85724 USA
[2] Univ Arizona, Dept Pathol, Tucson, AZ 85724 USA
[3] Univ Arizona, Mel & Enid Zuckerman Coll Publ Hlth, Tucson, AZ 85724 USA
[4] Univ Texas, MD Anderson Canc Ctr, Dept Pathol, Div Pathol & Lab Med, Houston, TX 77030 USA
[5] Denver Vet Adm Med Ctr, Coll Med, Sect Gastroenterol & Hepatol, Denver, CO USA
关键词
D O I
10.1158/1055-9965.EPI-06-0144
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
In colorectal tumorigenesis, Ki-ras proto-oncogene mutation often occurs early in the adenoma-adenocarcinoma sequence, whereas mutation of the p53 gene is associated with late progression to carcinoma. We evaluated the relationship of demographic and clinicopathologic characteristics to Ki-ras mutation and p53 gene product overexpression in 1,093 baseline sporadic colorectal adenomas from 926 individuals enrolled in a phase III recurrence prevention trial. Ki-ras mutation was found in 14.7% of individuals and p53 overexpression was found in 7.0% of those tested. Multivariate analysis found older age, rectal location, and villous histology to be independently associated with Ki-ras mutation. Individuals with an advanced adenoma (>= 1cm or high-grade dysplasia or villous histology) had a 4-fold higher likelihood of Ki-ras mutation [odds ratios (OR), 3.96; 95% confidence intervals (CI), 2.54-6.18]. Ki-ras mutations in codon 12 and of the G-to-A transition type were more frequent in older individuals, whereas G-to-T transversion was more frequent in rectal adenomas than in the colon. Multivariate analysis showed that previous history of a polyp (P = 0.03) was inversely associated with p53 overexpression. Large adenoma size (>= 1 cm), high-grade dysplasia, and villous histology were independently associated with p53 overexpression, with the strongest association for advanced adenomas (OR, 7.20; 95% CI, 3.01-17.22). Individuals with a Ki-ras mutated adenoma were more likely to overexpress p53 (OR, 2.46; 95% CI, 1.36-4.46), and 94.8% of adenomas with both alterations were classified as advanced (P <= 0.0001). Our large cross-sectional study supports the role of both Ki-ras and p53 in the progression of adenomas and shows that their molecular pathogenesis differs by anatomic location, age, and mucosal predisposition as evidenced by previous history of a polyp.
引用
收藏
页码:1443 / 1450
页数:8
相关论文
共 77 条
[1]  
Ahnen DJ, 1998, CANCER RES, V58, P1149
[2]   K-RAS GENE MUTATION RELATED TO HISTOLOGICAL ATYPIAS IN HUMAN COLORECTAL ADENOMAS [J].
AJIKI, T ;
FUJIMORI, T ;
IKEHARA, H ;
SAITOH, Y ;
MAEDA, S .
BIOTECHNIC & HISTOCHEMISTRY, 1995, 70 (02) :90-94
[3]   Lack of effect of a high-fiber cereal supplement on the recurrence of colorectal adenomas [J].
Alberts, DS ;
Martínez, ME ;
Roe, DJ ;
Guillén-Rodríguez, JM ;
Marshall, JR ;
van Leeuwen, JB ;
Reid, ME ;
Ritenbaugh, C ;
Vargas, PA ;
Bhattacharyya, AB ;
Earnest, DL ;
Sampliner, RE ;
Parish, D ;
Koonce, K ;
Fales, L .
NEW ENGLAND JOURNAL OF MEDICINE, 2000, 342 (16) :1156-1162
[4]   K-ras mutations and HLA-DR expression in large bowel adenomas [J].
Andersen, SN ;
Breivik, J ;
Lovig, T ;
Meling, GI ;
Gaudernack, G ;
Clausen, OPF ;
Schjolberg, A ;
Fausa, O ;
Langmark, F ;
Lund, E ;
Rognum, TO .
BRITISH JOURNAL OF CANCER, 1996, 74 (01) :99-108
[5]   HIGHER FREQUENCY OF POINT MUTATIONS IN THE C-K-RAS 2 GENE IN HUMAN COLORECTAL ADENOMAS WITH SEVERE ATYPIA THAN IN CARCINOMAS [J].
ANDO, M ;
MARUYAMA, M ;
OTO, M ;
TAKEMURA, K ;
ENDO, M ;
YUASA, Y .
JAPANESE JOURNAL OF CANCER RESEARCH, 1991, 82 (03) :245-249
[6]   Kirsten ras mutations in patients with colorectal cancer:: the 'RASCAL II' study [J].
Andreyev, HJN ;
Norman, AR ;
Cunningham, D ;
Oates, J ;
Dix, BR ;
Iacopetta, BJ ;
Young, J ;
Walsh, T ;
Ward, R ;
Hawkins, N ;
Beranek, M ;
Jandik, P ;
Benamouzig, R ;
Jullian, E ;
Laurent-Puig, P ;
Olschwang, S ;
Muller, O ;
Hoffmann, I ;
Rabes, HM ;
Zietz, C ;
Troungos, C ;
Valavanis, C ;
Yuen, ST ;
Ho, JWC ;
Croke, CT ;
O'Donoghue, DP ;
Giaretti, W ;
Rapallo, A ;
Russo, A ;
Bazan, V ;
Tanaka, M ;
Omura, K ;
Azuma, T ;
Ohkusa, T ;
Fujimori, T ;
Ono, Y ;
Pauly, M ;
Faber, C ;
Glaesener, R ;
de Goeij, AFPM ;
Arends, JW ;
Andersen, SN ;
Lövig, T ;
Breivik, J ;
Gaudernack, G ;
Clausen, OPF ;
De Angelis, P ;
Meling, GI ;
Rognum, TO ;
Smith, R .
BRITISH JOURNAL OF CANCER, 2001, 85 (05) :692-696
[7]   Kirsten ras mutations in patients with colorectal cancer: the multicenter "RASCAL" study [J].
Andreyev, HJN ;
Norman, AR ;
Cunningham, D ;
Oates, JR ;
Clarke, PA .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1998, 90 (09) :675-684
[8]   Activation of c-K-ras mutations in human gastrointestinal tumors [J].
Arber, N ;
Shapira, I ;
Ratan, J ;
Stern, B ;
Hibshoosh, H ;
Moshkowitz, M ;
Gammon, M ;
Fabian, I ;
Halpern, Z .
GASTROENTEROLOGY, 2000, 118 (06) :1045-1050
[9]   EVALUATION OF 6 ANTIBODIES FOR IMMUNOHISTOCHEMISTRY OF MUTANT P53 GENE-PRODUCT IN ARCHIVAL COLORECTAL NEOPLASMS [J].
BAAS, IO ;
MULDER, JWR ;
OFFERHAUS, GJA ;
VOGELSTEIN, B ;
HAMILTON, SR .
JOURNAL OF PATHOLOGY, 1994, 172 (01) :5-12
[10]  
Barletta A, 1998, ANTICANCER RES, V18, P1677